KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Liabilities (2016 - 2026)

TherapeuticsMD filings provide 17 years of Total Liabilities readings, the most recent being $10.6 million for Q1 2026.

  • On a quarterly basis, Total Liabilities fell 7.72% to $10.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.6 million, a 7.72% decrease, with the full-year FY2025 number at $10.8 million, down 5.87% from a year prior.
  • Total Liabilities hit $10.6 million in Q1 2026 for TherapeuticsMD, down from $10.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $274.0 million in Q1 2022 to a low of $10.6 million in Q1 2026.
  • Median Total Liabilities over the past 5 years was $13.4 million (2024), compared with a mean of $51.5 million.
  • Biggest five-year swings in Total Liabilities: grew 10.12% in 2022 and later crashed 89.93% in 2023.
  • TherapeuticsMD's Total Liabilities stood at $55.3 million in 2022, then tumbled by 74.65% to $14.0 million in 2023, then fell by 18.33% to $11.5 million in 2024, then decreased by 5.87% to $10.8 million in 2025, then dropped by 1.6% to $10.6 million in 2026.
  • The last three reported values for Total Liabilities were $10.6 million (Q1 2026), $10.8 million (Q4 2025), and $11.2 million (Q3 2025) per Business Quant data.